For years, China's brain-computer interface (脑机接口) story was a parade of one-off demos: a cursor moved here, a wheelchair steered there.
In August 2025, the story changed shape. Seven central ministries published a single document that treats brain-computer interface not as a science project but as a national industrial track — with deadlines, clusters, standards, and a named list of technologies to build.
It is the clearest signal yet that Beijing wants the field industrialized, not just admired.
Key takeaways
- Seven ministries — led by the Ministry of Industry and Information Technology (工业和信息化部) — jointly issued the Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry in August 2025.
- The plan sets a two-step target: by 2027, key technologies break through and electrode, chip, and device performance reach international advanced levels; by 2030, a safe and reliable industry system forms with 2–3 globally influential leading firms.
- It names three technical routes — invasive (植入式), semi-invasive, and non-invasive (非侵入式) — and calls for accelerating invasive-device R&D and mass-producing non-invasive devices.
- Five major tasks and three key engineering programs (17 measures in total) cover chips, whole devices, clinical application, and industry clusters.
What the document actually is
This is a formal implementation opinion (实施意见), jointly issued rather than a draft for comment. The seven signatories are the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Education, the National Health Commission, the State-owned Assets Supervision and Commission, the Chinese Academy of Sciences, and the National Medical Products Administration (国家药品监督管理局). That lineup matters: it pulls industrial policy, health regulation, research, and education into one coordinated push.
The 2027 and 2030 bar
The plan's spine is a two-step timeline:
- By 2027: core technologies achieve breakthroughs; preliminary advanced technology, industry, and standards systems are built; electrode, chip, and whole-device performance reach international advanced levels; brain-computer interface products accelerate adoption across industrial manufacturing, medical health, and consumer life; the industry scales up and 2–3 development clusters form.
- By 2030: innovation capability rises markedly; a safe and reliable industry system takes shape; 2–3 globally influential leading enterprises and a batch of specialized small firms emerge; an internationally competitive ecosystem forms and comprehensive strength enters the world's front rank.
The phrasing is aspirational, not legally binding, but the specificity — named years, named counts of clusters and firms — is unusual for a field often discussed in vague superlatives.
The three routes, named
Unlike many strategies that treat "BCI" as one blob, the opinion separates the technical paths:
- Invasive (植入式): accelerate R&D breakthroughs, including high-precision surgical robots for implantation with sub-micron (亚微米级) precision control.
- Non-invasive (非侵入式): push mass-production iteration — forehead patches, ear patches, in-ear and hairclip form factors — toward lighter, faster, lower-power consumer products.
- Assistive devices: develop supporting hardware.
It also calls out brain-signal sensing elements and critical BCI chips — high-channel, high-rate acquisition chips and ultra-low-power processing chips — as explicit攻关 (breakthrough) targets.
Beyond the lab: clusters, standards, money
The plan leans on three engineering programs: a core hardware/software foundation program, a whole-device quality program, and an application-expansion program. It urges priority registration support for implantable BCI medical devices, use of first-set insurance compensation policies, and greater investment from state-backed funds.
Market context, from CCID Consulting (赛迪顾问), helps explain the urgency: China's BCI market was about RMB 3.2 billion (≈ US$440M / HK$3.5B) in 2024 with 18.8% growth, and is projected to reach roughly RMB 6.1 billion (≈ US$850M / HK$6.7B) by 2028. By end-March 2025, per the China Academy of Information and Communications Technology, more than 1,000 BCI financing deals had been publicly disclosed globally and over 300 BCI companies funded.
According to Li An, chief scientist at BrainNet (脑机网), a national roadmap matters less for any single product and more for the standards, clusters, and reimbursement rails it builds underneath the whole field. Li An's comments reflect his own views and do not represent NeuroAI's editorial position or an endorsement by BrainNet (脑机网).
Why it is a signal, not a slogan
The document's weight comes from who signed it. When the medical-products regulator and the health commission sit at the same table as the industry and science ministries, the implication is that brain-computer interface is meant to move from papers to wards to reimbursement — the same arc that turned other Chinese tech tracks into global supply-chain players.
The opinion also explicitly frames BCI as a "future industry new track" (未来产业新赛道), the language Beijing uses for strategically prioritized emerging sectors.
Honest limitations
- This is a policy target document, not a binding law; the 2027/2030 figures are official aspirations, and we did not model their probability of being met.
- Market-size and financing figures are third-party estimates (CCID Consulting, CAICT) cited by state media; they are directional, not audited.
- The opinion covers national-level intent; provincial and hospital-level implementation will vary, and we did not track each local rollout.
- We did not assess how this plan interacts with overseas export controls or clinical-trial rules for invasive devices.
What readers can do now
- Track the three named routes — invasive, semi-invasive, non-invasive — and watch which Chinese firms win the priority registration and cluster support the plan promises.
- If you follow the sector, treat the 2027/2030 milestones as a checklist: verify, year by year, whether electrode/chip performance and cluster formation actually materialize rather than assuming them.
- For patients and clinicians, watch for the reimbursement and standards work the plan promises — that is what will decide whether BCI therapies become accessible, not the headline demos.
